Get weekly updates on this stock
VE | Creator | Signal |
|---|---|
 BRBrian Stoffel | Buy |
BRThe YouTuber added to Veeva, which he describes as the cloud service for the pharmaceutical industry, as part of a rebalancing due to the impact of agentic AI.
The YouTuber added to Veeva, which he describes as the cloud service for the pharmaceutical industry, as part of a rebalancing due to the impact of agentic AI.
“and I also added to Viva which is basically the cloud service for the pharmaceutical industry. Still debating on what I think about that based on the position size” — ▶ Watch clip
The YouTuber considers Viva 'robust' because it serves as the system of record for clinical trials, where errors would be existential for life sciences companies. This deterministic nature makes it highly resistant to AI disruption.
“Viva I think definitely has the system of record for clinical trials and missing messing up any one part of that is going to be existential to a life sciences company that's using it. So I don't see that going anywhere.” — ▶ 8:50
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
1 finance YouTubers analysed Veeva with qualified reasoning — consensus: Buy, average analysis quality 60/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Veeva, 1 are buying and 0 are selling or avoiding — overall Buy.
Only qualified analyses count: a clear buy/sell stance on Veeva with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.
Brian Stoffel